TRANSCODE THERAPEUTICS, INC.: 10-Q filed 2022-08-15

Name: TRANSCODE THERAPEUTICS, INC.: 10-Q filed 2022-08-15
Creator: TRANSCODE THERAPEUTICS, INC.

What TRANSCODE THERAPEUTICS, INC. reported in its quarterly report filed 2022-08-15 (fiscal Q2 2022): 35 published measures, 97 facts as tagged in accession 0001104659-22-091201.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-08-15
Fiscal period: fiscal Q2 2022
Accession: 0001104659-22-091201 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TRANSCODE THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-06-30	14,155,456	USD
At 2021-12-31	22,938,443	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-06-30	1,727,251	USD
At 2021-12-31	2,534,097	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-06-30	12,428,205	USD
At 2022-03-31	17,000,838	USD
At 2021-12-31	20,404,346	USD
At 2021-06-30	-5,036,081	USD
At 2021-03-31	-7,845,139	USD
At 2020-12-31	-3,408,232	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-06-30	13,438,385	USD
At 2021-12-31	20,825,860	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	-4,671,232	USD	91
2022-01-01 to 2022-06-30	-8,141,302	USD	181
2022-01-01 to 2022-03-31	-3,470,070	USD	90
2021-04-01 to 2021-06-30	2,770,904	USD	91
2021-01-01 to 2021-06-30	-1,714,434	USD	181
2021-01-01 to 2021-03-31	-4,485,338	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	-7,320,760	USD	181
2021-01-01 to 2021-06-30	-598,152	USD	181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	72,704	USD	181
2021-01-01 to 2021-06-30	97,541	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	5,989	USD	181
2021-01-01 to 2021-06-30	-52,756	USD	181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	-72,704	USD	181
2021-01-01 to 2021-06-30	-97,541	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-06-30	-18,446,583	USD
At 2021-12-31	-10,305,281	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	12,977,234	shares	91
2022-01-01 to 2022-06-30	12,977,234	shares	181
2021-04-01 to 2021-06-30	4,636,216	shares	91
2021-01-01 to 2021-06-30	4,636,216	shares	181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	12,977,234	shares	91
2022-01-01 to 2022-06-30	12,977,234	shares	181
2021-04-01 to 2021-06-30	5,400,184	shares	91
2021-01-01 to 2021-06-30	4,636,216	shares	181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	-0.36	USD/shares	91
2022-01-01 to 2022-06-30	-0.63	USD/shares	181
2021-04-01 to 2021-06-30	0.6	USD/shares	91
2021-01-01 to 2021-06-30	-0.37	USD/shares	181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	-0.36	USD/shares	91
2022-01-01 to 2022-06-30	-0.63	USD/shares	181
2021-04-01 to 2021-06-30	0.51	USD/shares	91
2021-01-01 to 2021-06-30	-0.37	USD/shares	181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	0	USD	91
2022-01-01 to 2022-06-30	0	USD	181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-06-30	234,673	USD
At 2021-12-31	206,268	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	159,172	USD	181
2021-01-01 to 2021-06-30	82,945	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	-4,707,293	USD	91
2022-01-01 to 2022-06-30	-8,184,795	USD	181
2021-04-01 to 2021-06-30	-355,528	USD	91
2021-01-01 to 2021-06-30	-804,993	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-06-30	13,920,783	USD
At 2021-12-31	22,732,175	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2021-04-01 to 2021-06-30	41,966	USD	91
2021-01-01 to 2021-06-30	94,736	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-06-30	1,727,251	USD
At 2021-12-31	2,534,097	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	4,707,293	USD	91
2022-01-01 to 2022-06-30	8,184,795	USD	181
2021-04-01 to 2021-06-30	355,528	USD	91
2021-01-01 to 2021-06-30	804,993	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	2,620,028	USD	91
2022-01-01 to 2022-06-30	4,501,604	USD	181
2021-04-01 to 2021-06-30	211,752	USD	91
2021-01-01 to 2021-06-30	475,511	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-06-30	12,977,234	shares
At 2021-12-31	12,904,574	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-06-30	13,438,385	USD
At 2021-12-31	20,825,860	USD
At 2021-06-30	79,567	USD
At 2020-12-31	828,016	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-06-30	30,873,490	USD
At 2021-12-31	30,708,336	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2022-06-30	320,226	USD
At 2021-12-31	247,522	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2022-06-30	85,553	USD
At 2021-12-31	41,254	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2022-06-30	482,398	USD
At 2021-12-31	1,906,315	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	-8,141,302	USD	181
2021-01-01 to 2021-06-30	-1,714,434	USD	181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	2,087,265	USD	91
2022-01-01 to 2022-06-30	3,683,191	USD	181
2021-04-01 to 2021-06-30	143,776	USD	91
2021-01-01 to 2021-06-30	329,482	USD	181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	44,299	USD	181
2021-01-01 to 2021-06-30	5,947	USD	181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	44,299	USD	181
2021-01-01 to 2021-12-31	42,470	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-04-01 to 2022-06-30	36,061	USD	91
2022-01-01 to 2022-06-30	43,493	USD	181
2021-04-01 to 2021-06-30	3,126,432	USD	91
2021-01-01 to 2021-06-30	-909,441	USD	181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2022-01-01 to 2022-06-30	5,129	USD	181

Inspect the source

Entity: TRANSCODE THERAPEUTICS, INC. / CIK 0001829635
Captured: 2026-09-21T17:29:25.770Z
SEC response SHA-256: 9f045b8c6b6066ebea672fd5e78fdf7e2d4af73b1e7786053a28677ad0402dc5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001829635.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))